It is pointed out that andrographolide is widely used in clinical practice because of its pharmacological effects such as clearing away heat and detoxification, anti-bacterial and anti-inflammatory, and has good research value. The effect of its modified compounds is mainly studied for pulmonary fibrosis. The company's ZBD0276 project is based on andrographolide, through chemical restructuring research and development. 
 

　　 ZBD said that the above "Patent Authorization Certificate" is the first international patent of andrographolide modification compound, and also the third American patent obtained by the company. It is another major progress in the company's international patent protection, and also a major progress in the company's innovative drug research. It is conducive to further improve the company's intellectual property protection system, give full play to the technical advantages of independent intellectual property, promote technological innovation, and thus enhance the company's core competitiveness.
 

　　 There are 11 dosage form products 
 

　　 Since the outbreak of the epidemic, the unique role of TCM has received more attention, renewed recognition and support. In Beijing, Nanjing, Jiangxi, Shanghai and Henan, local laws and regulations on TCM have been issued successively, including the Beijing Regulations on TCM and the Henan Provincial Key Work Points for TCM in 2020, pointing out the direction for TCM innovation and development and helping to further stimulate and release the potential and vitality of TCM. 
 

　　 According to the understanding of the rich financial network, ZBD is a traditional Chinese medicine industry based on the health industry as a modern pharmaceutical enterprise. The company integrates science and technology research and development, pharmaceutical industry, traditional Chinese medicine industry, financial investment four leading industries as one, the research and development work from traditional Chinese medicine to chemical medicine, biological medicine gradually expanded. 
 

　　 According to the "five-in-one" research and development strategy, ZBD Pharmaceutical promotes the research and development of innovative drugs and generic drugs. Company in line with the three "combination" working mode, through the reasonable layout of "research and development generation, planning generation", with traditional Chinese medicine, chemical medicine, biological medicine as the direction of development, constantly improve the level of research and development, to create three drug research and development technology platform and high-tech product cluster.
 

　　 At present, the company owns the producing, large capacity injection, injection, small volume injection agent, tablet, capsule, granule, syrup, oral solution, Fried 11 formulations including preparation, active pharmaceutical ingredients, products related to classes of heart head blood-vessel, colds, fractures and osteoporosis, enhance immunity, protect liver, etc. More than one category. 
 

　　 Treasured island, moreover, the first "Chinese herbal medicine + Internet + + + quality + warehousing logistics financial services industry form a complete set of" a new business model, set up modern large-scale B2B, B2C, wisdom of O2O commodities trading platform, borrows the technological innovation, product innovation, financial innovation and service innovation, industrial development, and stood in the whole industry chain of ecological circle core, integrate resources, establish standards, building industry, open for Chinese real economy service platform for the large system. 
 

　　 It has a research and development team of nearly 200 people 
 

　　 Treasured island adhere to scientific and technological innovation to promote enterprise rapid development, established the Chinese medicine, chemical medicine, biological medicine, collaborative development system of innovative research and development, the company has built a nearly 200 research and development team, set up a medical institute as the main research and development professional engaged in the study of new drug research and development and innovation, has been in Beijing, Shanghai and Harbin more built research institute, established the national post-doctoral scientific research workstation, provincial enterprise technology center and the provincial key laboratory of Chinese native medicine preparation process platform. 
 

　　 In terms of traditional Chinese medicine, in recent years the company continued in the field of traditional advantages of Chinese medicine research and development invested a lot of money and effort, the joint national well-known universities and research institutions, constantly on the secondary development of some existing mature products, with the Beijing university, zhejiang university, China academy of Chinese medicine academy of sciences, Shanghai pharmaceutical industry and so on more than a dozen research institutes cooperation, in-depth study on efficacy material base, quality control method, evidence-based medicine, exclusive varieties introduced, etc. 
 

　　 In the field of TCM formula granules, ZBD Pharmaceutical has actively participated in the formulation of national standards and established a research and development platform for formula granules. At present, 430 varieties have been registered in Heilongjiang Province, and the process and quality standard research of 120 varieties is being carried out successively, and it is expected that 550 varieties will be registered in Heilongjiang Province in the future. 
 

　　 At present, in the aspect of chemical medicine on optimized product structure is mainly to research and develop the generic drugs, the company's metformin hydrochloride approved by consistent evaluation of generic drugs, hydrochloric acid ammonia bromine cable injection project has 130/0.4 complete registration filing, hydroxyethyl starch injection project also completed the additional information submitted, and in the real trial stage. 
 

　　 In the optimization of enterprise r&d product line, to carry out the international generic drugs research and development, the company has cooperation with guangzhou bo think 瑫 development China and the United States developed a generic items to declare, and Taiwan of generic drug company to negotiate the introduction of advanced technology, such as cooperation with India PHARMASOL company introduce advanced generic technology, with India to BE the sale of generic drugs companies import registration, etc. 
 

　　 At present, the company has won two new drugs for testing, one of the products years for phase I clinical trials, one used in the treatment of idiopathic pulmonary fibrosis of the new drug has completed IND declare registration, at the same time the company spent 150 million yuan to introduce has completed the phase I clinical anti-flu drug HNC042 project, are pushing ahead with phase II clinical trial related work. 
 

　　 It has 157 national patents 
 

　　 It is worth mentioning that ZBD has always paid attention to the protection of intellectual property rights of its products. As of June 30, 2020, there have been 157 national patents. The leading products of the company, Xuesaitong injection and Shuxuening injection, are all patent protected products, and other reserve varieties have also obtained patent rights. "Vinyl Compounds as FGFR and VEGFR Inhibitors" and "Andrographolide Modified Compounds" were granted patents in the United States;Dihydropyrazole azazepines as inhibitors of Akt are licensed for patents in the United States and Europe.
 

　　 Company in the process of production, creatively adopts the technology of the continuous hot reflux extraction, macroporous resin adsorption technology, microwave vacuum drying technology, membrane filtration technology and extraction process automation control technology, the near infrared spectrum technology, fingerprint spectrum technology, digital process technology and so on more than 10 domestic and international advanced technology, applied to the various stages of development and production of different products, improve product technology content and quality. 
 

　　 In addition, ZBD has established internal quality control standards higher than the national drug standards for each drug in combination with the relevant requirements of national drug standards and technical standards of the Chinese Pharmacopoeia, and has improved the indicators of key drug inspection items. According to the internal control standards of the enterprise, the products are released from the factory, and some products are up to the international standards. 
 

　　 The company has an independent quality control center and measurement center, which successfully obtained the accreditation qualification of CNAS testing laboratory and calibration laboratory. The approved capability covers all inspection items of the company's products.
 

　　 At present, all the preparation forms of ZBD have obtained the new GMP certificate, and also obtained the registration license and production license of disposable medical masks. The company and its subsidiary, Hajiaozhen, have passed the ISO9001 quality management system certification, ISO14000 environmental management system certification, and ISO18000 health and safety management system certification, and are operating effectively. The company has established a leading domestic after-sales service management system in the same industry, and passed the "double five star" brand and service certification.